The Motley Fool
22 Nov 2026, 18:03 UTC · 1h ago
Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors
Impact · against what's priced in
The article provides no new catalyst for Eli Lilly as its pipeline strength and recent revenue beats are already central to the current valuation. The price drops for the other listed tickers are incidental market data and not driven by the article's content.
- LLY+0.00
Already priced in
- The price assumes
Deceleration from the just-delivered 44.7% revenue growth
The article's praise for Zepbound's 'outstanding' sales and the potential of the pipeline to maintain leadership are already reflected in the price, which assumes a 32.6% CAGR and current high-growth guidance.





